Mangalam Drugs And Organics Limited
Mangalam Drugs And Organics Limited (MANGALAM) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
mangalamdrugs.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 Cr | 97 Cr | 102 Cr | 77 Cr | 80 Cr | 89 Cr | 73 Cr | 57 Cr | 50 Cr | 58 Cr | 67 Cr | 57 Cr |
| Operating expenses (approx.) | 0 Cr | 90 Cr | 91 Cr | 68 Cr | 71 Cr | 80 Cr | 63 Cr | 62 Cr | 52 Cr | 60 Cr | 73 Cr | 56 Cr |
| EBITDA | 0 Cr | 7 Cr | 12 Cr | 8 Cr | 9 Cr | 9 Cr | 10 Cr | -4 Cr | -3 Cr | -1 Cr | -6 Cr | 0.90 Cr |
| OPM % | -0.7% | 7.2% | 11.4% | 10.7% | 10.9% | 9.9% | 13.9% | -7.8% | -5.7% | -2.4% | -8.4% | 1.6% |
| Other income | 0 Cr | 0.0019 Cr | 0.05 Cr | 0.02 Cr | 0.14 Cr | 0.14 Cr | 0.21 Cr | 0.0004 Cr | 0.03 Cr | 0.11 Cr | 0.09 Cr | 0.11 Cr |
| Interest | 0 Cr | 3 Cr | 4 Cr | 4 Cr | 4 Cr | 3 Cr | 4 Cr | 4 Cr | 5 Cr | 4 Cr | 3 Cr | 4 Cr |
| Depreciation | 0 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 5 Cr | 4 Cr | 5 Cr | 4 Cr | 5 Cr | 4 Cr |
| Profit before tax | 0 Cr | 0.04 Cr | 4 Cr | 0.58 Cr | 1 Cr | 1 Cr | 2 Cr | -13 Cr | -12 Cr | -10 Cr | -13 Cr | -7 Cr |
| Tax % | 12.9% | -1091.1% | 10.1% | -359.2% | -124.2% | 5.9% | 96.4% | -6.2% | 41.1% | -0.0% | -1.1% | -13.2% |
| Net profit | 0 Cr | 0.50 Cr | 4 Cr | 3 Cr | 3 Cr | 1 Cr | 0.06 Cr | -14 Cr | -7 Cr | -10 Cr | -13 Cr | -8 Cr |
| EPS (₹) | ₹0.00 | ₹0.31 | ₹2.23 | ₹1.70 | ₹1.70 | ₹0.81 | ₹0.04 | ₹-8.72 | ₹-4.64 | ₹-6.21 | ₹-8.48 | ₹-4.83 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 369 Cr | 318 Cr | 232 Cr | Sign in for TTM |
| Operating expenses (approx.) | 351 Cr | 282 Cr | 247 Cr | Sign in for TTM |
| EBITDA | 17 Cr | 36 Cr | -15 Cr | Sign in for TTM |
| OPM % | 4.7% | 11.3% | -6.4% | Sign in for TTM |
| Other income | 0.10 Cr | 0.50 Cr | 0.76 Cr | Sign in for TTM |
| Interest | 14 Cr | 15 Cr | 16 Cr | Sign in for TTM |
| Depreciation | 15 Cr | 17 Cr | 18 Cr | Sign in for TTM |
| Profit before tax | -11 Cr | 5 Cr | -49 Cr | Sign in for TTM |
| Tax % | 18.1% | -40.4% | 8.6% | Sign in for TTM |
| Net profit | -9 Cr | 7 Cr | -44 Cr | Sign in for TTM |
| EPS (₹) | ₹-5.73 | ₹4.25 | ₹-28.05 | Sign in for TTM |
| Dividend payout % | — | 0.0% | — | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 16 Cr | 16 Cr | 16 Cr |
| Reserves | 120 Cr | 133 Cr | 87 Cr |
| Borrowings | 88 Cr | 81 Cr | 105 Cr |
| Other liabilities | 110 Cr | 136 Cr | 106 Cr |
| Total liabilities | 333 Cr | 366 Cr | 315 Cr |
| Fixed assets (net) | 104 Cr | 134 Cr | 116 Cr |
| CWIP | 0 Cr | 0 Cr | 0 Cr |
| Investments | 0.0044 Cr | 0.0044 Cr | 0.0044 Cr |
| Loans & advances | 1 Cr | 1 Cr | 0.05 Cr |
| Inventories | 124 Cr | 139 Cr | 103 Cr |
| Trade receivables | 28 Cr | 39 Cr | 40 Cr |
| Cash & bank | 0.90 Cr | 3 Cr | 0.70 Cr |
| Other assets | 76 Cr | 51 Cr | 55 Cr |
| Total assets | 333 Cr | 366 Cr | 315 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operating activity | -11 Cr | 43 Cr | 4 Cr |
| Cash from investing | 0 Cr | -19 Cr | -12 Cr |
| Cash from financing | 0 Cr | -22 Cr | 6 Cr |
| Net cash flow | -11 Cr | 1 Cr | -2 Cr |
| Free cash flow (OCF − Capex) | -11 Cr | 22 Cr | -8 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | 1.3% | 8.6% | -15.5% |
| ROE % | 0.0% | 0.0% | 0.0% |
| Debtor days | 28 | 45 | 63 |
| Inventory days | 201 | 296 | 300 |
| Days payable | 107 | 195 | 221 |
| Cash conversion cycle | 121 | 146 | 142 |
| Debt / equity | 0.65 | 0.54 | 1.02 |
| Current ratio | 1.07 | 1.04 | 0.79 |
| Net debt / EBITDA | 5.00 | 2.19 | — |
Compare with peers
Loading peers…